Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

  • Acute Leukemias (R Stone, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Disease relapse remains a major cause of mortality for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Historically, patients who experience disease relapse after HSCT have a dismal prognosis with very few long-term survivors. There is no standard treatment for patients in this situation given the variability in patient characteristics, disease biology, complications such as graft-vs.-host disease (GVHD) and infections, donor availability, and patient choice. Here, we discuss the current options for treatment of relapsed AML after HSCT including conventional chemotherapy, novel agents, donor leukocyte infusion, second allogeneic HSCT, and emerging therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Chen YB, Spitzer TR. Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia. 2008;22:31–41.

    Article  PubMed  Google Scholar 

  3. Ballen KK, Koreth J, Chen YB, et al. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012;119:1972–80.

    Article  CAS  PubMed  Google Scholar 

  4. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Brunner AM, Kim HT, Coughlin E, et al. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013;19:1374–80.

    Article  PubMed  Google Scholar 

  6. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306:1874–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. van den Brink MR, Porter DL, Giralt S, et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010;16:S138–45.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Reese ND, Schiller GJ. High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malignancy Rep. 2013;8:141–8.

    Article  Google Scholar 

  9. Chevallier P, Prebet T, Pigneux A, et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia. 2010;24:467–9.

    Article  CAS  PubMed  Google Scholar 

  10. Kurosawa S, Yamaguchi T, Miyawaki S, et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica. 2010;95:1857–64.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Herzig RH, Wolff SN, Lazarus HM, et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62:361–9. This study, and several which followed it, established the tolerability and efficacy of high-dose cytarabine (HiDAC) as single agent, and subsequently in combination with other cytotoxic agents, in the treatment of relapsed or refractory AML, including those who relapse following transplant. Three decades later, HiDAC is still a commonly used component of re-induction therapies.

    CAS  PubMed  Google Scholar 

  12. Momparler RL. A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1974;34:1775–87.

    CAS  PubMed  Google Scholar 

  13. Rudnick SA, Cadman EC, Capizzi RL, et al. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer. 1979;44:1189–93.

    Article  CAS  PubMed  Google Scholar 

  14. Early AP, Preisler HD, Slocum H, et al. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res. 1982;42:1587–94.

    CAS  PubMed  Google Scholar 

  15. Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87:256–64.

    CAS  PubMed  Google Scholar 

  16. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116–24.

    CAS  PubMed  Google Scholar 

  17. Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol. 2003;82:231–5.

    CAS  PubMed  Google Scholar 

  18. Robak T, Wrzesien-Kus A, Lech-Maranda E, et al. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2000;39:121–9.

    Article  CAS  PubMed  Google Scholar 

  19. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115–26.

    Article  CAS  PubMed  Google Scholar 

  20. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991;9:1210–4.

    CAS  PubMed  Google Scholar 

  21. Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood. 1987;69:744–9.

    CAS  PubMed  Google Scholar 

  22. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004;103:784–9.

    Article  CAS  PubMed  Google Scholar 

  23. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379–86.

    Article  CAS  PubMed  Google Scholar 

  24. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res. 1996;56:3030–7.

    CAS  PubMed  Google Scholar 

  25. Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011;155:182–9.

    Article  CAS  PubMed  Google Scholar 

  26. Tse E, Leung AY, Sim J, et al. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol. 2011;90:1277–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012;30:2492–9.

    Article  CAS  PubMed  Google Scholar 

  28. Patel C, Stenke L, Varma S, et al. Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity. Cancer. 2013;119:3076–83.

    Article  PubMed  Google Scholar 

  29. Kantarjian HM, Keating MJ, Walters RS, et al. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol. 1988;6:232–8.

    CAS  PubMed  Google Scholar 

  30. Coral S, Sigalotti L, Gasparollo A, et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother. 1999;22:16–24.

    Article  CAS  PubMed  Google Scholar 

  31. Pinto A, Maio M, Attadia V, et al. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine. Lancet. 1984;2:867–8.

    Article  CAS  PubMed  Google Scholar 

  32. Oran B, de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol. 2011;18:388–94.

    Article  CAS  PubMed  Google Scholar 

  33. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116:1908–18.

    Article  CAS  PubMed  Google Scholar 

  34. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009;115:1899–905.

    Article  CAS  PubMed  Google Scholar 

  35. Bolanos-Meade J, Smith BD, Gore SD, et al. 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2011;17:754–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 2010;45:627–32.

    Article  CAS  PubMed  Google Scholar 

  37. Czibere A, Bruns I, Kroger N, et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant. 2010;45:872–6.

    Article  CAS  PubMed  Google Scholar 

  38. Graef T, Kuendgen A, Fenk R, et al. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res. 2007;31:257–9.

    Article  CAS  PubMed  Google Scholar 

  39. Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27:1229–35.

    Article  CAS  PubMed  Google Scholar 

  40. Schroeder T, Frobel J, Cadeddu RP, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27:1910–3.

    Article  CAS  PubMed  Google Scholar 

  41. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010;28:4919–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Ford CD, Asch J, Konopa K, et al. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45:403–4.

    Article  CAS  PubMed  Google Scholar 

  43. Attar EC, Amrein PC, Fraser JW, et al. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013;37:1016–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012;12:341–4.

    Article  CAS  PubMed  Google Scholar 

  45. Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia. 2007;21:586–8.

    Article  CAS  PubMed  Google Scholar 

  46. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist. 2011;16:1162–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776–84.

    Article  CAS  PubMed  Google Scholar 

  48. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.

    Article  CAS  PubMed  Google Scholar 

  49. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  CAS  PubMed  Google Scholar 

  50. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  PubMed  Google Scholar 

  51. Winkler J, Rech D, Kallert S, et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. Leuk Res. 2010;34:e270–2.

    Article  CAS  PubMed  Google Scholar 

  52. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113:6567–71.

    Article  CAS  PubMed  Google Scholar 

  53. Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26:2353–9. Sorafenib was among the first tyrosine kinase inhibitors to be studied as a FLT3 inhibitor in AML, and was demonstrated in this study to be an effective therapy for patients with FLT3-mutant disease who relapse following allogeneic transplantation. Other potent and specific FLT3 inhibitors are currently under study as therapies in those with relapsed disease.

    Article  CAS  PubMed  Google Scholar 

  54. Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2012;17:1874–7.

    Article  Google Scholar 

  55. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31:3681–7.

    Article  CAS  PubMed  Google Scholar 

  56. Levis MJ, Perl AE, Dombret H, et al.: Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts) 120:Abstract 673, 2012.

  57. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 2002;20:405–12.

    Article  CAS  PubMed  Google Scholar 

  58. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;41:483–93.

    Article  CAS  PubMed  Google Scholar 

  59. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25:4938–45. This is the largest analysis to date of patients who have received DLI for relapsed disease after allogeneic HSCT. It analyzes clinical factors, which predict for an increased success from such a strategy.

    Article  CAS  PubMed  Google Scholar 

  60. Bar M, Sandmaier BM, Inamoto Y, et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant. 2013;19:949–57.

    Article  PubMed  Google Scholar 

  61. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant. 2008;42:569–79.

    Article  CAS  PubMed  Google Scholar 

  62. Soiffer RJ. Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2008;21:455–66.

    Article  CAS  PubMed  Google Scholar 

  63. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev. 2014;257:127–44.

    Article  CAS  PubMed  Google Scholar 

  64. Blau IW, Basara N, Bischoff M, et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant. 2000;25:41–5.

    Article  CAS  PubMed  Google Scholar 

  65. Bosi A, Bacci S, Miniero R, et al. Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Leukemia. 1997;11:420–4.

    Article  CAS  PubMed  Google Scholar 

  66. Chiang KY, Weisdorf DJ, Davies SM, et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant. 1996;17:39–42.

    CAS  PubMed  Google Scholar 

  67. Kishi K, Takahashi S, Gondo H, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant. 1997;19:461–6.

    Article  CAS  PubMed  Google Scholar 

  68. Mehta J, Powles R, Treleaven J, et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant. 1997;19:709–19.

    Article  CAS  PubMed  Google Scholar 

  69. Christopoulos P, Schmoor C, Waterhouse M, et al. Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. Bone Marrow Transplant. 2013;48:901–7.

    Article  CAS  PubMed  Google Scholar 

  70. Leung AY, Tse E, Hwang YY, et al. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor. Am J Hematol. 2013;88:485–91.

    Article  PubMed  Google Scholar 

  71. Christopeit M, Kuss O, Finke J, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259–71. This is the largest analysis to date analyzing any effect of changing donors when undertaking a 2nd allogeneic HSCT for relapsed disease. Perhaps it is limited by numbers, but the data here suggests there is no significant difference when a different donor is used, yet also shows the feasibility of using an unrelated donor for the 2nd HSCT.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Amir T. Fathi served on the advisory board for Agios Pharmaceutical and Seattle Genetics.

Dr. Yi-Bin Chen served as a consultant for Otsuka Pharmaceuticals and Seattle Genetics. Dr. Chen received grants from Otsuka, Seattle Genetics, Bayer/Onyx, and Novartis, Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Center for Leukemia, Massachusetts General Hospital, Zero Emerson Place, Suite 118, Boston, MA, 02114, USA

    Amir T. Fathi

  2. Bone Marrow Transplant Unit, Cox 108, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA

    Yi-Bin Chen

Authors
  1. Amir T. Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi-Bin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi-Bin Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fathi, A.T., Chen, YB. Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Curr Hematol Malig Rep 9, 186–192 (2014). https://doi.org/10.1007/s11899-014-0209-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-014-0209-2

Keywords

Search

Navigation